Introduction
============

Esophageal cancer is one of the most common malignancies worldwide.[@b1-ott-11-7385],[@b2-ott-11-7385] Although a combination of radical esophageal cancer resection and chemotherapy has been widely used, the 5-year overall survival rate is still relatively low owing to the difficulty in early diagnosis of esophageal cancer.[@b3-ott-11-7385],[@b4-ott-11-7385] Consequently, the search for effective molecular markers for screening, early diagnosis, and prognosis for the high-risk groups of esophageal cancer is a clinical hotspot. In recent years, molecular studies have helped elucidate many abnormal biological events that occur during the development of esophageal cancer and thus aided in screening a series of specific therapeutic targets and biological markers, which could contribute to better understanding of the underlying biology.[@b5-ott-11-7385]--[@b7-ott-11-7385]

CircRNA is a novel endogenous RNA, which is highly expressed in the eukaryotic transcriptome. In contrast to lncRNAs and miRNAs, circRNAs have a covalently closed continuous looP, instead of 5′--3′ polarity and polyadenylated tails.[@b8-ott-11-7385],[@b9-ott-11-7385] Owing to this special stable structure, circRNAs can participate in various biological functions with increased biological stability. CircRNAs have a high degree of tissue-specific expression, indicating that their roles might differ for various sites and species. The multiple functions of circRNAs have gradually been elucidated, for example, circRNAs can act as miRNA sponges, regulate splicing and transcription, bind to proteins, and transport specific RNAs.[@b8-ott-11-7385],[@b10-ott-11-7385] In recent years, emerging evidence has shown that circRNAs may also play a key role in tumor development.[@b11-ott-11-7385],[@b12-ott-11-7385]

CircRNA_100876 is a circRNA oriented from chr11: 71668272--71671937.[@b13-ott-11-7385] This circRNA (encoded by *RNF121*) can be regulated as a ceRNA. CircRNA_100876 regulates the expression of MMP13, which is usually correlated with cancer occurrence and development.[@b13-ott-11-7385]--[@b15-ott-11-7385] To date, circRNA_100876 has been found to be highly expressed in lung cancer, with its high expression being negatively correlated with the prognosis of non-small-cell lung cancer,[@b16-ott-11-7385] suggesting that circRNA_100876 promotes metastatic potential.

The expression pattern and biological function of circRNA_100876 in esophageal squamous cell carcinoma (ESCC) remain unknown. Therefore, we analyzed circRNA_100876 expression in ESCC and tried to clarify the relationship between clinicopathologic parameters and circRNA_100876 expression in ESCC, including the prognostic value of circRNA_100876. More importantly, we knocked down circRNA_100876 expression in esophageal cancer cells, observed its effects on proliferation and metastasis, and analyzed the possible mechanisms underlying these effects.

Materials and methods
=====================

Tissue samples
--------------

Human ESCC and paired adjacent noncancerous tissues were obtained from 74 patients who had undergone radical excision without receiving any other treatment before surgery and been pathologically diagnosed with ESCC between 2011 and 2014. All specimens were immediately frozen in liquid nitrogen after excision and stored at -80°C. The Ethics Committee of Nanfang Hospital, Southern Medical University approved this research. The informed consent form regarding specimen use for scientific research was signed by each patient.

Cell culture
------------

The ESCC cell lines, Eca-109 and TE-1, were obtained from the National Infrastructure of Cell Line Resource (Shanghai, China), the KYSE-410 and KYSE-150 cell lines were purchased from Deutsche Sammlung von Mikroorganismen und Zellkulturen (Braunschweig, Germany), and the immortalized esophageal epithelial cell line, HEEC, was obtained from ScienCell Research Laboratory (Carlsbad, CA, USA). KYSE-410, KYSE-150, and HEEC cells were cultured in Roswell Park Memorial Institute 1640 medium (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% FBS (Thermo Fisher Scientific); ECA-109 and TE-1 cells were cultured in DMEM (Thermo Fisher Scientific) supplemented with 10% FBS. The cells were maintained at 37°C in a humidified atmosphere with 5% CO~2~.

RNA interference
----------------

To establish cell lines with stable knockdown, lentiviruses expressing siRNAs against circRNA_100876 (siRNA-1 and siRNA-2 cells) and the negative control (NC cells) sequence (Genechem, Shanghai, China) were constructed. TE-1 and KYSE-150 cells were transfected with a mixture of lentivi-ruses (multiplicity of infection, 100) and 5 µg/mL polybrene. After 72 hours, the transfected cells were used for further analysis. The siRNAs targeting circRNA_100876 and NC sequences are presented in [Table 1](#t1-ott-11-7385){ref-type="table"}.

Total RNA extraction and real-time quantitative PCR (RT-qPCR) assays
--------------------------------------------------------------------

Total RNA was extracted from the frozen tissues and cell lines with TRIzol reagent (Thermo Fisher Scientific) and 500 ng total RNA was reverse transcribed to cDNA with the PrimeScript RT Master Mix (TaKaRa, Dalian, China) as per the respective manufacturer's instruction. Then, the relative circRNA_100876 expression, normalized to expression of the endogenous control β-actin, was determined by RT-qPCR assays using the SYBR Premix Ex Taq II Kit (TaKaRa) on the StepOnePlus system (Thermo Fisher Scientific). Fold changes were calculated using the 2^-ΔΔCt^ method.[@b17-ott-11-7385] The primers used for RT-qPCR assay are presented in [Table 1](#t1-ott-11-7385){ref-type="table"}.

Cell viability and proliferation assays
---------------------------------------

Cell viability and proliferation were analyzed using Cell Counting Kit-8 (CCK-8), colony-formation, and 5-ethynyl-2´-deoxyuridine (EdU)-incorporation assays.

For the CCK-8 assay, 3×10^3^ cells per well were seeded into 96-well plates. Their viability was measured at 0, 24, 48, 72, and 96 hours after adherence by using CCK-8 (Solarbio, Beijing, China) as per the manufacturer's protocol; absorbance was recorded at 450 nm using a microplate reader.

For the colony-formation assay, cells (200/well) were seeded into six-well plates. After incubation for another 2 weeks, colonies with diameter greater than 1 mm were counted after staining with 0.5% crystal violet.

For the EdU-incorporation assay, 3×10^3^ cells for each well were seeded into 96-well plates. The Cell-Light EdU imaging kit (RiboBio, Guangzhou, China) was used in accordance with the manufacturer's instructions. Images were captured under an inverted fluorescence microscope (Olympus, Tokyo, Japan).

Animal study
------------

The anti-growth effect of circRNA_100876 silencing on ESCC cell line was determined in vivo after receiving approval from the Ethics Committee of Nanfang Hospital, Southern Medical University. Specific-pathogen-free-- grade male nude mice (age 3--4 weeks) were bought from the Experimental Animal Center of Guangdong Province, Guangzhou, China. The transfected TE-1 cells were cultured, harvested, and washed with PBS buffer, and then subcutaneously injected into the flanks of the mice (1×10^7^/200 µL for each nude mouse). All mice were raised and maintained in specific-pathogen-free--grade environment in accordance with the National Institutes of Health USA (2011) Guide for the Care and Use of Laboratory Animals.[@b18-ott-11-7385] The tumor volumes were measured and calculated every 4 days using the following formula: volume = (length × width × width)/2.

Flow cytometric analyses
------------------------

Cell cycle distribution and apoptotic cell proportion were analyzed on a FACSCanto II flow cytometer (BD Biosciences) and detected using a cell cycle detection kit (Keygen, Nanjing, China) and the Annexin V-fluorescein isothiocyanate/propidium iodide apoptosis detection kit (Keygen), respectively, as per the manufacturers' instructions.

Transwell migration and invasion assays
---------------------------------------

The cell migration and invasion abilities were evaluated by Transwell assays performed using Transwell chambers (0.8 µm; Corning Incorporated, Corning, NY, USA) with or without Matrigel coating (Corning Incorporated). The complete medium was added to the lower chambers, and 5×10^4^ cells suspended in serum-free medium were then added into the upper compartments. After 24-hour incubation, nonmigrating and noninvading cells were removed from the upper surface of the membranes, while the cells remaining on the other side were fixed and stained with 0.5% crystal violet and digitally imaged.

Western blotting assay
----------------------

Total proteins were extracted from cell lines by using RIPA (Beyotime, Shanghai, China) buffer supplemented with the protease inhibitor phenylmethanesulfonyl fluoride (1:100; Beyotime). After detecting the protein concentrations by using the bicinchoninic acid (Beyotime) method, equivalent total protein was separated by 10% SDS-PAGE (Fdbio Science, Hangzhou, China) and transferred onto polyvinylidene difluoride membranes (EMD Millipore, Billerica, MA, USA). The membranes were then blocked with TBST solution containing 5% skimmed milk (Solarbio) for 1 hour at room temperature and incubated with primary antibodies at 4°C overnight. The primary antibodies used (all from Proteintech, Rosemont, IL, USA) were as follows: anti-cyclin D1 rabbit polyclonal antibody (1:500), anti-cyclin B1 rabbit polyclonal antibody (1:1,000), anti-E-cadherin rabbit polyclonal antibody (1:1,000), anti-N-cadherin rabbit poly-clonal antibody (1:1,000), anti-vimentin rabbit polyclonal antibody (1:2,000), anti-snail rabbit polyclonal antibody (1:500), and anti-β-actin rabbit polyclonal antibody (1:5,000). Subsequently, the membranes were incubated with HRP-labeled goat anti-rabbit secondary antibody (1:10,000; Proteintech) for 1 hour at room temperature; the protein bands were visualized with an enhanced chemiluminescence substrate kit (Fdbio Science) on FluorChem E system (ProteinSimple, San Jose CA, USA). The densitometric analysis of the protein bands was conducted using AlphaView SA version 3.4.0.0 (ProteinSimple).

Statistical analyses
--------------------

Results have been presented as mean ± standard error of the mean. All statistical analyses were performed using the Pearson chi-squared test, two-tailed Student's *t*-test, or ANOVA, as appropriate, with either GraphPad Prism 7.0 (GraphPad Software, Inc., La Jolla, CA, USA) or IBM SPSS Statistics 20.0 (IBM Corporation, Armonk, NY, USA). Survival data were evaluated using the Kaplan--Meier method and the log-rank test. *P*\<0.05 was considered statistically significant.

Results
=======

CircRNA_100876 was upregulated in ESCC and predicted poor prognosis
-------------------------------------------------------------------

To determine the potential role of circRNA_100876 in ESCC, the relative circRNA_100876 expression in ESCC tissues, the correlation between circRNA_100876 expression and clinicopathologic characteristics, and postoperative survival times were analyzed. RT-qPCR showed that circRNA_100876 expression was significantly higher in ESCC tissues than in adjacent normal tissues (*P*\<0.001; [Figure 1A](#f1-ott-11-7385){ref-type="fig"}); in ESCC tissues, it was upregulated in 71.6% of the samples (53/74; [Figure 1B](#f1-ott-11-7385){ref-type="fig"}). Using the medium expression value of circRNA_100876 as the cut-off point for the Pearson chi-squared test and Kaplan--Meier's plot, it was found that circRNA_100876 expression was strongly correlated with tumor invasion depth (*P*=0.017), lymph node metastasis (*P*=0.027), and vascular invasion (*P*=0.036; [Table 2](#t2-ott-11-7385){ref-type="table"}). Patients with higher circRNA_100876 expression had shorter recurrence-free survival (median, 41 vs 23 months; *P*=0.029; [Figure 1C](#f1-ott-11-7385){ref-type="fig"}) and overall survival time (median, 46 vs 30 months; *P*=0.021; [Figure 1D](#f1-ott-11-7385){ref-type="fig"}) than those with lower circRNA_100876 expression, indicating that circRNA_100876 expression was linked to the clinical progression of ESCC and might represent a promising prognostic biomarker.

CircRNA_100876 was knocked down in ESCC cells
---------------------------------------------

To gain insight into the biological significance of circRNA_100876 in ESCC development and progression, loss-of-function experiments were performed. Endogenous circRNA_100876 expression levels were studied in a panel of ESCC cell lines. CircRNA_100876 expression was upregu-lated in the ESCC cell lines, especially in TE-1 and KYSE-150 cells, compared with the human immortal esophageal epithelial cell line HEEC ([Figure 1E](#f1-ott-11-7385){ref-type="fig"}). Subsequently, TE-1 and KYSE-150 cells with stably silenced circRNA_100876 expression were established, and validated with RT-qPCR ([Figure 1F](#f1-ott-11-7385){ref-type="fig"}).

CircRNA_100876 knockdown suppressed cell proliferation in vitro and in vivo
---------------------------------------------------------------------------

In vitro analysis with CCK-8 and colony-formation assays showed that circRNA_100876 knockdown markedly reduced the proliferative capacity of ESCC cells ([Figure 2A and B](#f2-ott-11-7385){ref-type="fig"}). A similar tendency was noted in the EdU-incorporation assay: the proportion of EdU-positive cells decreased in circRNA_100876-silenced ESCC cells ([Figure 2C](#f2-ott-11-7385){ref-type="fig"}). Besides, the anti-growth effect of TE-1 cells transfected with siRNA-1 or NC sequence was compared using in vivo tumorigenicity assay. The average volume of xenograft tumors grown from circRNA_100876-knockdown TE-1 cells was 75.27±7.51 mm^3^ at day 16, while that of the mice inoculated with NC sequence-infected TE-1 cells was 472.20±142.71 mm^3^, which was significantly larger than that of circRNA_100876 silencing group (*P*\<0.05; [Figure 2D](#f2-ott-11-7385){ref-type="fig"}). What is more, the difference in tumor size between the two groups rose over time and peaked at day 28, the endpoint (444.88±99.68 vs 1,561.32±349.22 mm[@b3-ott-11-7385], *P*\<0.05; [Figure 2D](#f2-ott-11-7385){ref-type="fig"}). These results showed that circRNA_100876 silencing can restrict ESCC cell growth both in vitro and in vivo.

CircRNA_100876 knockdown led to G2/M phase arrest and apoptosis in vitro
------------------------------------------------------------------------

To determine the initial mechanism by which circRNA_100876 modulated ESCC cell proliferation, the alterations in the cell cycle and apoptosis were also analyzed after circRNA_100876 knockdown. The cell populations with circRNA_100876 knockdown showed increased percentages of G2/M phase cells and decreased percentages of G1 phase cells; there was no obvious change in S phase cells ([Figure 3A](#f3-ott-11-7385){ref-type="fig"}). Consistent with the aforementioned data, the expression of the G2/M phase checkpoint protein cyclin B1 was upregulated, while the G1 phase checkpoint protein cyclin D1 decreased when circRNA_100876 was depleted ([Figure 3B](#f3-ott-11-7385){ref-type="fig"}). Flow cytometric analysis based on the Annexin V/propidium iodide method showed that the apoptotic cell count (Annexin V positive) was significantly higher in circRNA_100876 knockdown groups than in the control group ([Figure 3C](#f3-ott-11-7385){ref-type="fig"}). Hence, circRNA_100876 depletion restricted ESCC progression, partially by eliminating cell cycle arrest and inhibiting apoptosis.

CircRNA_100876 knockdown suppressed migration, invasion, and epithelial--mesenchymal transition (EMT) in vitro
--------------------------------------------------------------------------------------------------------------

CircRNA_100876 promotes extracellular matrix degradation by competing with MMP13 for miR-136.[@b13-ott-11-7385] Given that relative circRNA_100876 expression was significantly correlated with invasion depth, lymph node metastasis, and vascular invasion, we hypothesized that circRNA_100876 might participate in regulating ESCC metastasis. The metastatic potential of ESCC cells with circRNA_100876 knockdown was markedly inhibited, in accordance with the decrease in migrating and invading cells shown by Transwell assays ([Figure 4A](#f4-ott-11-7385){ref-type="fig"}). The EMT process was also restrained after circRNA_100876 knockdown, which was characterized by upregulation of epithelial-phenotype E-cadherin and downregulation of mesenchymal-phenotype N-cadherin, vimentin, and the EMT-associated transcription factor Snail ([Figure 4B](#f4-ott-11-7385){ref-type="fig"}). Therefore, we concluded that circRNA_100876 promoted cell migration, invasion, and EMT progression in ESCC, thus facilitating cancer metastasis.

Discussion
==========

CircRNAs have been implicated in cancer biology.[@b11-ott-11-7385],[@b19-ott-11-7385] They are associated with the occurrence and development of several human cancer types, wherein they may function as cancer promoters or suppressors.[@b20-ott-11-7385]--[@b26-ott-11-7385] Altered circ_100876 expression has been identified in lung squamous cell carcinoma.[@b16-ott-11-7385] However, little is known about its role in ESCC. To our knowledge, the current study is the first to analyze the expression pattern and biological value of circ_100876 in ESCC. Circ_100876 expression levels in ESCC tissues were markedly higher than those in the corresponding noncancerous tissues. Moreover, there was a significant correlation between elevated circ_100876 expression and the presence of lymph node metastasis, advanced tumor staging, and poor prognosis of ESCC patients. Our findings indicate that circRNA_100876 should be considered as a crucial molecular marker for ESCC patients.

To elucidate the function of circRNA_100876 in ESCC occurrence and development, in vitro and in vivo assays were performed using circRNA_100876-targeting siRNAs to knock down circRNA_100876 in the ESCC cell lines. CircRNA_100876 knockdown could suppress proliferation, induce apoptosis of ESCC cells, and arrest cell cycle in the G2/M phase. CircRNA_100876 depletion reduced tumor growth in nude mice. These results validated the hypothesis that circRNA_100876 may function as an oncogene and serves an important function in ESCC cell proliferation. In addition, circRNA_100876 knockdown remarkably weakened the migration and invasion capabilities of ESCC cells, indicating that circRNA_100876 might enhance metastasis in ESCC. These findings coupled with our discovery of the positive relationship between tissue circRNA_100876 expression and lymph node metastasis suggested that elevated circRNA_100876 expression in ESCC tissues might enhance distant metastasis and thus result in unfavorable outcomes in ESCC patients.

EMT, an important hallmark of cancer progression, involves transformation of epithelial cells to a mesenchymal cell phenotype via a pathophysiological mechanism.[@b27-ott-11-7385]--[@b29-ott-11-7385] The relationship between EMT and circRNAs in cancer metastasis has attracted considerable attention recently; most research has focused on the expression of the EMT-associated regulatory factor, including the epithelial marker E-cadherin and the mesenchymal markers N-cadherin and vimentin.[@b30-ott-11-7385],[@b31-ott-11-7385] In the current study, we found that circRNA_100876 depletion led to upregulation of the protein levels of E-cadherin and downregulation of N-cadherin and vimentin in ESCC cells, suggesting that absence of circRNA_100876 might reverse EMT process. Therefore, we believe that circRNA_100876 might promote metastasis by activating EMT in ESCC.

Conclusion
==========

Taken together, circRNA_100876 is found to be upregulated in ESCC tissues and may contribute to ESCC initiation and progression. Knockdown of circRNA_100876 suppressed proliferation, migration, and invasion of ESCC cells through modulating EMT process. Our analysis of circRNA_100876 provides new insights into disease mechanisms; circRNA_100876 should be considered as a potential biomarker and therapeutic target for ESCC. Our study revealed important findings, but is still limited by lack of comprehensive analysis of the functional role of circRNA_100876 as an endogenous sponge. The clinical significance of our data is limited because only tissue samples were used from humans; it would increase greatly if circRNA_100876 could be successively detected in the circulatory system. CircRNAs exhibit strong regulatory effects in cancer; they combine with miRNAs to regulate their function.[@b32-ott-11-7385] Additional studies to elucidate the functional mechanisms of circRNA_100876 in ESCC and other cancers are essential.
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![CircRNA_100876 expression in ESCC tissues, correlation analyses with postoperative survival, and construction of circRNARNA_100876 knockdown cell models.\
**Notes:** (**A**) CircRNA_100876 expression was significantly higher in ESCC tissues than in adjacent normal tissues evaluated by RT-qPCR. (**B**) The relative circRNA_100876 expression was upregulated in 71.6% (53/74) patients with ESCC, revealed as the form of Log2 (T/N). (**C**) Correlation between circRNA_100876 expression and postoperative recurrence-free survival. (**D**) Correlation between circRNA_100876 expression and postoperative overall survival. (**E**) CircRNA_100876 expression in ESCC cell lines and the human immortal esophageal epithelial cell line HEEC detected by RT-qPCR. (**F**) Construction of circRNA_100876-knockdown ESCC cell models and quantitation by RT-qPCR. *\*\*P*\<0.01, *\*\*\*P*\<0.001.\
**Abbreviations:** ESCC, esophageal squamous cell carcinoma; NC, negative control; RT-qPCR, real-time quantitative PCR.](ott-11-7385Fig1){#f1-ott-11-7385}

![CircRNA_100876 knockdown inhibited tumor growth and proliferation in vitro and in vivo.\
**Notes:** (**A**) Stable knockdown of circRNA_100876 suppressed viability of TE-1 and KYSE-150 cells, detected using CCK-8 assay. (**B**) CircRNA_100876 silencing decreased colony-formation rates of TE-1 and KYSE-150 cells, determined using colony-formation assays. (**C**) Stable knockdown of circRNA_100876 inhibited cellular DNA replication in TE-1 and KYSE-150 cells, detected by EdU-incorporation assays (magnification, 200×). (**D**) CircRNA_100876 knockdown in TE-1 cells restrained tumor growth in nude mice. *\*P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001.\
**Abbreviations:** CCK-8, Cell Counting Kit-8; DAPI, 4′,6-diamidino-2-phenylindole; NC, negative control.](ott-11-7385Fig2){#f2-ott-11-7385}

![CircRNA_100876 knockdown led to cell cycle arrest and induced apoptosis of ESCC cells.\
**Notes:** (**A**) The percentage of G1 phase cells significantly decreased and that of G2/M phase cells increased after stable knockdown of circRNA_100876 in TE-1 and KYSE-150 cells, revealed by FACS analysis. (**B**) Stable knockdown of circRNA_100876 upregulated cyclin B1 expression and downregulated cyclin D1 expression evaluated by Western blotting and subsequent densitometric analysis. (**C**) The percentage of late-stage apoptotic cells was increased after circRNA_100876 knockdown in TE-1 and KYSE-150 cells, revealed by FACS analysis. *\*\*P*\<0.01, \*\*\**P*\<0.001.\
**Abbreviations:** ESCC, esophageal squamous cell carcinoma; FACS, Fluorescence-activated cell sorting; NC, negative control.](ott-11-7385Fig3){#f3-ott-11-7385}

![CircRNA_100876 knockdown inhibited migration, invasion, and epithelial--mesenchymal transition in ESCC cells.\
**Notes:** (**A**) Stable silencing of circRNA_100876 significantly inhibited migration and invasion by TE-1 and KYSE-150 cells, measured by Transwell assays. (**B**) Western blotting and densitometric analysis showed upregulation of the epithelial marker E-cadherin, downregulation of the mesenchymal markers N-cadherin and vimentin, and the decrease in the epithelial--mesenchymal transition--associated transcription factor Snail after circRNA_100876 knockdown. \**P*\<0.05, \*\**P*\<0.01, *\*\*\*P*\<0.001.\
**Abbreviations:** ESCC, esophageal squamous cell carcinoma; NC, negative control.](ott-11-7385Fig4){#f4-ott-11-7385}

###### 

Sequences of oligomers and primers used in the present research

  Name                     Sequence (5′--3′)
  ------------------------ -------------------------------
                           
  Si-circRNA_100876-1      CAC GCT CCT ACA ATG TTG ATA
  Si-circRNA_100876-2      CCA CGC TCC TAC AAT GTT GAT
  Negative control         TTC TCC GAA CGT GTC ACG TTT
  CircRNA_100876 forward   CTG GTG CAG TGG AAG CAG AG
  CircRNA_100876 reverse   CGA CCC TCC ATT GCT CTT CT
  β-actin forward          CGC TCT CTG CTC CTC CTG TTC
  β-actin reverse          ATC CGT TGA CTC CGA CCT TCA C

###### 

Correlation analysis between the relative circRNA_100876 expression and clinicopathologic parameters of patients with ESCC (*N*=74)

  Clinicopathologic parameters   Number of cases                CircRNA_100876 expression           
  ------------------------------ ----------------- ------------ --------------------------- ------- -----------
                                                                                                    
  Gender                                                                                            0.802
   Male                          51                26 (51.0%)   25 (49.0%)                  0.063   
   Female                        23                11 (47.8%)   12 (52.2%)                          
  Age, years                                                                                        0.475
   \<60                          45                21 (46.7%)   24 (53.3%)                  0.510   
   ≥60                           29                16 (55.2%)   13 (44.8%)                          
  Tumor size, cm                                                                                    0.439
   \<3                           21                12 (57.1%)   9 (42.9%)                   0.598   
   ≥3                            53                25 (47.2%)   28 (52.8%)                          
  Invasion depth                                                                                    **0.017**
   pT1+pT2                       19                14 (73.7%)   5 (26.3%)                   5.736   
   pT3+pT4                       55                23 (41.8%)   32 (58.2%)                          
  Lymph node metastasis                                                                             **0.027**
   Positive                      49                20 (40.8%)   29 (59.2%)                  4.893   
   Negative                      25                17 (68.0%)   8 (32.0%)                           
  Vascular invasion                                                                                 **0.036**
   Positive                      20                6 (30.0%)    14 (70.0%)                  4.385   
   Negative                      54                31 (57.4%)   23 (42.6%)                          
  Differentiation                                                                                   0.797
   Poor + moderate               53                26 (49.1%)   27 (50.9%)                  0.066   
   Well                          21                11 (52.4%)   10 (47.6%)                          
  Metastasis                                                                                        0.286
   Positive                      9                 3 (33.3%)    6 (66.7%)                   1.138   
   Negative                      65                34 (52.3%)   31 (47.7%)                          

**Note:** Bold values indicate *P*\<0.05.

**Abbreviation:** ESCC, esophageal squamous cell carcinoma.
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